Apricoxib
Legal status | |
---|---|
Legal status |
|
Identifiers | |
| |
JSmol) | |
| |
|
Apricoxib is an experimental anticancer drug and
COX-2 inhibitor which is intended to improve standard therapy response in molecularly-defined models of pancreatic cancer.[2] It was also studied in clinical trials for non-small-cell lung cancer.[3] Development was abandoned in 2015 due to poor clinical trial results.[4]
See also
References
- ^ "Apricoxib (Code C74021)". NCI Thesaurus. National Cancer Institute.
- PMID 22829202.
- PMID 25452446.
- ^ "Apricoxib". Adis Insight. Springer Nature Switzerland AG.